AFC
ADPT icon

Ares Financial Consulting’s Adaptive Biotechnologies ADPT Stock Holding History

Ares Financial Consulting’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.3K Hold
715
– – 0.01% 479
2026
Q1 		$10.3K Hold
715
– – 0.01% 538
2025
Q4 		$11.6K Buy
+715
New +$11.7K 0.01% 328

Other funds holding ADPT

Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
AWM
Affinity Wealth Management Wilmington, Delaware $776M AUM 43.59% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.21B AUM 82.36% 1-Year Est. Return

Ares Financial Consulting's ADPT Position: Q2 2026 in Review

Ares Financial Consulting held its Adaptive Biotechnologies (ADPT) position steady in Q2 2026 at 715 shares worth $15.3K. The position accounts for 0.01% of the portfolio, ranked #479.

Ares Financial Consulting first reported a position in ADPT in Q4 2025 and has held it in 3 quarters since. 104 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Ares Financial Consulting held 715 shares of Adaptive Biotechnologies worth $15.3K as of Q2 2026.
  • Ares Financial Consulting left its Adaptive Biotechnologies share count unchanged in Q2 2026.
  • Adaptive Biotechnologies made up 0.01% of Ares Financial Consulting's portfolio in Q2 2026, its #479 holding.
  • Ares Financial Consulting first reported a position in Adaptive Biotechnologies in Q4 2025 and has held it in 3 quarters since.
  • 104 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.